Contract Pharma Manufacturing News

  1. Cellipont Bioservices And BobcatBio Announce Strategic Collaboration To Advance Macrophage Cell Therapy For Solid Tumors 3/17/2026

    Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration with BobcatBio, a clinical-stage biotechnology company that is pioneering the development of RB-1355, a first of its kind cellular therapy that leverages the versatility and power of a patient's macrophages to elicit a robust, targeted tumoricidal immune response while substantially reducing or eliminating the reliance on traditional cancer treatments such as chemotherapy, high-dose radiation and surgery, thereby improving patient outcomes and quality of life.

  2. CEO Insights And Trends: The Future Of The Sterile Filling CDMO Industry 3/17/2026

    Denis Johnson, CEO, explores developments in the CDMO sector and reveals how GRAM is gearing up for its latest phase of growth in sterile filling.

  3. OPTEL And Kaster Technologies Partner To Bring AI-Driven Production Planning Intelligence To Pharma 3/17/2026

    OPTEL, a global leader in traceability and compliance solutions, and Kaster Technologies, a specialist in AI-powered production planning intelligence software, have announced a strategic commercial partnership to help pharmaceutical manufacturers increase production capacity and improve operational efficiency.

  4. Apertura Gene Therapy And Viralgen Announce Strategic Collaboration To Manufacture TfR1 CapX, A Next-Generation Capsid For Gene Therapies Designed To Treat Central Nervous System Diseases 3/17/2026

    Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, today announced a strategic manufacturing collaboration to support gene therapy programs using Apertura's TfR1 CapX, a novel AAV capsid that targets human Transferrin Receptor 1 (hTfR1) to cross the blood-brain barrier.

  5. Sentynl Therapeutics Enters Into Agreement With PRG S&T To License Molecule For Hutchinson-Gilford Progeria Syndrome 3/16/2026

    Sentynl Therapeutics Inc. ("Sentynl"), a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited ("Zydus"), announced that it is entering into an agreement with PRG S&T, a Korean company specializing in the development of medicine for rare genetic diseases, to license its investigational molecule Progerinin (SLC-D011) for Hutchinson-Gilford Progeria Syndrome (HGPS or "progeria").

  6. George Medicines Extends Global Commercialization Of GMRx2 Into Australia And New Zealand With Arrotex Licensing Agreement 3/16/2026

    George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Arrotex Pharmaceuticals (“Arrotex”), a leading Australian pharmaceutical company and Australia’s largest supplier of medicines by prescription volume, granting Arrotex exclusive rights to seek regulatory approval of, and to commercialize, GMRx2 in Australia.

  7. BD Announces $110 Million To Support U.S. Pharmaceutical Supply Chain For Biologic Drugs 3/16/2026

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $110 million investment to expand its production of prefillable syringes, helping accelerate biologic and GLP-1 drug delivery and supporting pharmaceutical reshoring in the U.S.

  8. Sartorius Launches Next-Generation Platform To Boost Efficiency In Cell Therapy Production 3/16/2026

    The life science group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies.

  9. BD And Ypsomed Expand Partnership To Address Rapidly Growing Biologics Market 3/16/2026

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Ypsomed, a leading developer of injection systems, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe.

  10. 3PBIOVIAN And INC Partner To Expand Access To Oncology Treatments In Colombia Through Biosimilar Development 3/13/2026